Franklin Genomic Advancements ETF
HELX
8 hedge funds and large institutions have $3.53M invested in Franklin Genomic Advancements ETF in 2021 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
84% more capital invested
Capital invested by funds: $1.92M → $3.53M (+$1.62M)
60% more funds holding
Funds holding: 5 → 8 (+3)
38.25% more ownership
Funds ownership: 43.26% → 81.51% (+38%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$741K |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$481K |
| 3 |
FTUS
Flow Traders U.S.
New York
|
+$314K |
| 4 |
APA
American Portfolios Advisors
Holbrook,
New York
|
+$267K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$23.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$291K |
| 2 |
BFEC
Benjamin F. Edwards & Company
St. Louis,
Missouri
|
-$16.7K |
HELX Hedge Fund Activity: Q1 2021 in Review
8 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Franklin Genomic Advancements ETF (HELX) for Q1 2021, worth a combined $3.53M — up 84% from $1.92M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new HELX positions and 1 closed out — a net gain of 3 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Jane Street, adding an estimated $741K. The largest seller was Cambridge Investment Research Advisors, exiting entirely with an estimated $291K sold.
- 8 institutional investors held Franklin Genomic Advancements ETF (HELX) as of Q1 2021, up from 5 in Q4 2020.
- Funds reported $3.53M of Franklin Genomic Advancements ETF stock for Q1 2021, up 84% quarter-over-quarter.
- 4 funds opened new Franklin Genomic Advancements ETF positions in Q1 2021 and 1 closed out, a net change of +3 holders.
- The largest Franklin Genomic Advancements ETF buyer in Q1 2021 was Jane Street, an estimated $741K added.
- The largest Franklin Genomic Advancements ETF seller in Q1 2021 was Cambridge Investment Research Advisors, an estimated $291K sold.
Based on aggregated 13F filings for Q1 2021.